Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 49

References for PMC Articles for PubMed (Select 21858171)

1.

Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.

Stoppoloni D, Canino C, Cardillo I, Verdina A, Baldi A, Sacchi A, Galati R.

Mol Cancer. 2010 Feb 2;9:27. doi: 10.1186/1476-4598-9-27.

2.

Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.

Crispi S, Cardillo I, Spugnini EP, Citro G, Menegozzo S, Baldi A.

Curr Cancer Drug Targets. 2010 Feb;10(1):19-26. Review.

PMID:
20088796
3.

Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target.

Crispi S, Calogero RA, Santini M, Mellone P, Vincenzi B, Citro G, Vicidomini G, Fasano S, Meccariello R, Cobellis G, Menegozzo S, Pierantoni R, Facciolo F, Baldi A, Menegozzo M.

PLoS One. 2009 Sep 15;4(9):e7016. doi: 10.1371/journal.pone.0007016.

4.

p21 in cancer: intricate networks and multiple activities.

Abbas T, Dutta A.

Nat Rev Cancer. 2009 Jun;9(6):400-14. doi: 10.1038/nrc2657. Review.

5.

Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.

Røe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S.

Lung Cancer. 2010 Jan;67(1):57-68. doi: 10.1016/j.lungcan.2009.03.016. Epub .

PMID:
19380173
6.

Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis.

Romagnoli S, Fasoli E, Vaira V, Falleni M, Pellegrini C, Catania A, Roncalli M, Marchetti A, Santambrogio L, Coggi G, Bosari S.

Am J Pathol. 2009 Mar;174(3):762-70. doi: 10.2353/ajpath.2009.080721. Epub 2009 Feb 13.

7.

Targeted therapies in breast cancer: established drugs and recent developments.

Fischgräbe J, Wülfing P.

Curr Clin Pharmacol. 2008 May;3(2):85-98. Review.

PMID:
18690883
8.

Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.

Spugnini EP, Crispi S, Scarabello A, Caruso G, Citro G, Baldi A.

J Exp Clin Cancer Res. 2008 May 19;27:6. doi: 10.1186/1756-9966-27-6.

9.

Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability.

Verdina A, Cardillo I, Nebbioso A, Galati R, Menegozzo S, Altucci L, Sacchi A, Baldi A.

J Transl Med. 2008 May 22;6:27. doi: 10.1186/1479-5876-6-27.

10.

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.

Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC.

Br J Haematol. 2008 May;141(5):598-606. doi: 10.1111/j.1365-2141.2008.07044.x. Epub 2008 Apr 7.

PMID:
18397345
11.

Survivin, cancer networks and pathway-directed drug discovery.

Altieri DC.

Nat Rev Cancer. 2008 Jan;8(1):61-70. Review.

PMID:
18075512
12.

Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma.

Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D, Deraco M, Daidone MG.

Cell Oncol. 2007;29(6):453-66.

PMID:
18032822
13.

oneChannelGUI: a graphical interface to Bioconductor tools, designed for life scientists who are not familiar with R language.

Sanges R, Cordero F, Calogero RA.

Bioinformatics. 2007 Dec 15;23(24):3406-8. Epub 2007 Sep 17.

14.

The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon-alpha through the inhibition of multiple survival pathways.

Caraglia M, Marra M, Viscomi C, D'Alessandro AM, Budillon A, Meo G, Arra C, Barbieri A, Rapp UR, Baldi A, Tassone P, Venuta S, Abbruzzese A, Tagliaferri P.

Int J Cancer. 2007 Nov 15;121(10):2317-30. Erratum in: Int J Cancer. 2008 Apr 15;122(8):1922.

PMID:
17657738
15.

Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.

Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.

Cancer Chemother Pharmacol. 2008 Apr;61(4):549-58. Epub 2007 May 24.

PMID:
17522864
16.

Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests.

Kim KW, Mutter RW, Willey CD, Subhawong TK, Shinohara ET, Albert JM, Ling G, Cao C, Gi YJ, Lu B.

Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1519-25.

PMID:
17394948
17.

Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma.

Spugnini EP, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, Nebbioso A, Altucci L, Cortese G, Galati R, Chien J, Shridhar V, Vincenzi B, Citro G, Cognetti F, Sacchi A, Baldi A.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6133-43.

18.

KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2 interaction.

Okamoto K, Kitabayashi I, Taya Y.

Biochem Biophys Res Commun. 2006 Dec 8;351(1):216-22. Epub 2006 Oct 12.

PMID:
17056014
19.

FoxM1: at the crossroads of ageing and cancer.

Laoukili J, Stahl M, Medema RH.

Biochim Biophys Acta. 2007 Jan;1775(1):92-102. Epub 2006 Aug 30. Review.

PMID:
17014965
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk